Antimony Trisulfide Atropa Belladonna Calcium Fluo

證據等級: L5

預測適應症: 0 個

Multi-Component Homeopathic Preparation: Insufficient Data for Drug Repurposing Evaluation

One-Sentence Summary

This submission contains a complex, multi-ingredient homeopathic formula (including Atropa Belladonna, Mercurius Solubilis, Sepia Officinalis, Hekla Lava, and eight other constituents) with no established original indication on record. The TxGNN model returned no predicted indications for this candidate, and no supporting clinical trials or publications were identified. Without a DrugBank ID, approved regulatory status, or any mechanistic data, this candidate cannot be assessed for repurposing at this time.

Quick Overview

Item	Content
Original Indication	Not recorded
Predicted New Indication	None — TxGNN returned no candidates
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only — no predictions generated)
Market Status	Not marketed
Number of Licenses	0
Recommended Decision	Hold

Why No Prediction Is Available

This formula is a multi-component preparation whose individual constituents are predominantly classical homeopathic agents:

Mineral/inorganic: Antimony Trisulfide, Calcium Fluoride, Hydrofluoric Acid, Lead, Silicon Dioxide, Tribasic Calcium, Oyster Shell Calcium Carbonate (Calc Carb), Hekla Lava (Icelandic volcanic ash)
Botanical: Atropa Belladonna
Mercury-based homeopathic: Mercurius Solubilis
Animal-derived: Sepia Officinalis Juice (cuttlefish ink)

The combination pattern — particularly Hekla Lava, Calcium Fluoride, and Calc Carb — is characteristic of homeopathic dental or bone-related preparations in classical homeopathic practice. However, none of the ingredients carry an established pharmacological mechanism of action (MOA) in the conventional pharmacological sense, and no DrugBank ID was resolved for the compound or any of its components.

TxGNN operates on a knowledge graph built from conventional drug–disease relationships. Because this formula has no DrugBank node and no conventional pharmacological profile, it falls outside the model’s prediction domain, which explains the empty predicted_indications result.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Market Information

This preparation has no regulatory licenses on file. It is not marketed and has not received any approvals.

Safety Considerations

Please refer to the package insert for safety information.

Note: Several ingredients in this formula carry significant toxicological concern if used outside homeopathic dilution ranges. Lead and Hydrofluoric Acid are acutely toxic substances; Atropa Belladonna contains anticholinergic alkaloids (atropine, scopolamine). Any future evaluation must explicitly document the dilution levels (e.g., 6X, 30C) used in the formulation, as toxicity profiles differ entirely between homeopathic dilutions and pharmacologically active doses.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate cannot be assessed for drug repurposing because the TxGNN model generated no predictions, the compound has no regulatory history, no DrugBank mapping, and no pharmacological MOA data — all essential prerequisites for a meaningful repurposing evaluation.

To proceed, the following is needed:

Confirm compound identity: Clarify whether this is a single registered homeopathic product; if so, obtain the brand name and full product monograph
Resolve DrugBank mapping: Attempt to map individual active constituents (e.g., Atropa Belladonna alkaloids) to DrugBank entries separately for any partial analysis
Document dilution levels: Homeopathic preparations are highly dilution-dependent; toxicological and pharmacological assessment requires knowing the potency (X/C/LM scale) for each ingredient
Re-run TxGNN on individual constituents: If any ingredient maps to a DrugBank node (e.g., atropine from Belladonna), a sub-component repurposing analysis may be feasible
Obtain package insert: Source the product monograph or regulatory dossier to populate the safety and indication fields before re-evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.